Managing Director

Alberto Libanori, PhD brings over a decade of experience at the science-business interface in venture capital, Business Development & Licensing, M&A and IPOs, focusing in life-sciences, med-tech and cosmeceuticals, at leading firms including L’Oréal, Merck KGaA, and Novartis Venture Funds. Previously Alberto founded and engineered strategic exits for technology start-ups including Atelier Mnemist SAS and Cutech (acquired by Symrise). He is currently an Independent Director on the Board of Nasdaq-listed Mainz Biomed B.V. (MYNZ), a molecular diagnostic company, Brera Holdings PLC (BREA), a multi-club ownership company in global football, and The RoyaLand Company Limited, a Bermuda company focused on royal themed massively multiplayer online role-playing game. A prolific scientist, Alberto has published more than 40 peer-reviewed papers including first-authored articles in Nature Electronics, Advanced Materials, and Nano Energy, and is holder of two patents. His work has been cited more than 2,000 times.

​

Alberto holds both a PhD and an MS in Bioengineering from UCLA, where he specialized in wearable and implantable bioelectronics and biomaterials for regenerative medicine. He also earned an MPhil in Bioscience Enterprise from Cambridge University in the UK, and a Bachelor’s Degree in Bimolecular Sciences (Hons) from St Andrews University in Scotland. 

​

Raised internationally, Alberto is fluent in English, French, Spanish, Mandarin Chinese, and Portuguese, alongside his native Italian. 

​

He holds FINRA Series 79 and SIE licenses.

​